Journal of Heterocyclic Chemistry · 1999 · 13 citations · 11 references
PharmacyMedicinal ChemistryPharmaceutical AnalysisDrug MetabolismOrganic ChemistryPharmaceutical ToxicologyBiodegradationDegradation Product AnalysisDegradation ProductsPhotochemistryChromatographic SelectivityMass Spectrometric IdentificationMass Spectrometric ScreeningMorpholine ChemistryPhotolytic DegradationPhotooxidationPhotosensitizing CompoundsSpectroscopic Identification
Abstract Parenteral formulations of linezolid (PNU‐100766), a novel ( S )‐3‐(4′‐fluorophenyl)‐5‐ N ‐acetamidomethyloxazolidin‐2‐one antibiotic, were subjected to photo‐stability testing as required by ICH guidelines. Direct, reversed phase chromatographic evaluation of the photo‐irradiated solutions revealed two chromatographically broad degradants. Following preparative chromatographic isolation, the structures of both degradants were determined by mass spectrometric, nmr, and vibrational spectroscopic methods. The degradant structures formed by decomposition involving photo‐oxidation of the morpholine, followed by a carbon‐carbon bond scission to a formyloxyethylformamide‐containing degradant. Facile hydrolytic cleav age of the formate ester in acidic media gave the second chromatographically broad degradant containing a N ‐2‐hydroxyethylformamide group. The formamide substituent underwent further hydrolysis in acidic media to the corresponding secondary amine.
11
Steven J. Brickner, Douglas K. Hutchinson, Michael R. Barbachyn et al. · Journal of Medicinal Chemistry · 1996 · 573 citations